Hanall Biopharma (South Korea)
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson’s Disease HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update Our Promise is to discover and develop innovative medicines to fulfill unmet medical needs. We value integrity and the highest standards for all bus
Basic Information
- Category: pharmaceutical industry
- Website: http://en.hanall.co.kr/main
Documented Facts
- Email: ineffable@hanall.co.kr (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore pharmaceutical industry profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Hanall Biopharma (South Korea).
- Canonical profile: https://brandsource.ai/brands/hanall-biopharma-south-korea
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/hanall-biopharma-south-korea/json-ld
- Citation profile API: https://brandsource.ai/api/brands/hanall-biopharma-south-korea/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson’s Disease HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update Our Promise is to discover and develop innovative medicines to fulfill unmet medical needs. We value integrity and the highest standards for all bus
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.